Keywords: analysts, raise, npvs, promacta, rezonic, tykerb, still

Analysts raise NPVs of Promacta and Rezonic; Tykerb still star of GSK oncology pipeline

Article | 02 July 2007

Print This

At a recent meeting held in London, UK drug major GlaxoSmithKline updated analysts on the latest developments in its oncology ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in